Our Alzheimer Research

Clinical Trials Interest Online Survey

If you are interested in learning more about our clinical trials, please fill out your information at the following link:

Alzheimer Research Online Survey Form

Research Studies

At Brigham and Women's Center for Alzheimer Research and Treatment (CART), we conduct two major types of clinical research studies: Observational or natural history studies and Interventional or therapeutic clinical trials. In observational studies, participants undergo memory and thinking tests as well as brain imaging scans. Researchers at CART are working on developing more sensitive cognitive tests, biomarkers and neuroimaging techniques like MRI and PET scans to detect early brain changes related to Alzheimer’s disease (AD), and to differentiate these changes from “normal aging”. In the therapeutic clinical trials, participants receive an experimental drug or a placebo to test new potential therapies to treat Alzheimer’s disease. CART is currently enrolling participants in multiple studies, including studies for older individuals with normal cognition, subjects with mild cognitive impairment (MCI), and patients who have been diagnosed with mild Alzheimer’s disease dementia. Please see information about individual studies below.

Clinical Trials

Our center is currently conducting clinical trials of treatments for people with mild-to-moderate Alzheimer's disease and mild cognitive impairment. Participants in clinical trials may benefit from the added monitoring, support, and information received during the trial, but it is important to understand both the potential risk and benefits of participation before enrolling. For general information about clinical trials, including a list of questions to ask when considering a trial, please see our Resources section or call us at 617-732-8085. For specific information about trials, including eligibility requirements, please see the individual trial listings below.

The EARLY Trial
Does Alzheimer’s Disease run in your family? The EARLY Trial is assessing the effectiveness and safety of an investigational medication to prevent the development of symptoms of Alzheimer's disease. The sponsor of this study is Janssen pharmaceutical company. More information...

The Aware Study
Are you having difficulty with forgetfulness, planning, or problem-solving? The Aware Study assesses the effectiveness and safety of an investigational medication to determine whether it can reduce symptoms in early Alzheimer's disease. The sponsor of the Aware Study is AbbVie pharmaceutical company. More information....

The Mission AD Study
Do you feel your memory isn't what it used to be? The Mission AD Study is assessing the effectiveness and safety of an investigational medication to improve the symptoms of Alzheimer's disease. The sponsor of this study is Eisai pharmaceutical company. More information...

The ENGAGE Trial
Are you having memory problems or trouble thinking clearly? The ENGAGE Trial assesses the effectiveness and safety of an investigational medication to determine whether it can slow the progression of symptoms in early AD. The sponsor of the ENGAGE Trial is Biogen, Inc. More information...

Observational Studies

The ADNI-3 Study
Want to help us improve our understanding of how Alzheimer's disease develops and progresses? The ADNI-3 study will create a national database of brain aging to improve clinical trials and provide researchers across the country with data to study how quickly brain cognition and function changes. The study is funded by the NIH. More information…

The Harvard Aging Brain Study
The goal of this study is to find out whether results of a brain scan are related to memory changes that occur in healthy older adults. Healthy adults between the ages of 65-90 are eligible to enroll. More information...

Dominantly Inherited Alzheimer Network (DIAN)
Research suggests that brain changes may occur years before actual Alzheimer’s symptoms are detected. The major goal of DIAN is to study these changes in people who carry an AD mutation to determine how the disease process develops before there are any symptoms. Ultimately, knowledge gained from DIAN may lead to tests that detect people who are still normal but are at very high risk of developing dementia caused by AD. More information...